Intravitreal Recombinant Human Erythropoietin: A Safety Study in Rabbits

REFERENCES

• Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health. 2006; 6: 58
   PubMed Web of Science ®Google Scholar
• Kass M A, Heuer D K, Higginbotham E J, et al. The ocular hypertension treatment study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120: 701–713, discussion 829–730
   PubMed Web of Science ®Google Scholar
• Comparison o f. glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998; 126: 487–497
   PubMed Web of Science ®Google Scholar
• The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000; 130: 429–440
   PubMed Web of Science ®Google Scholar
• Anderson D R, Drance S M, Schulzer M. Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. Am J Ophthalmol. 2003; 136: 820–829
   PubMed Web of Science ®Google Scholar
• Leskea M C, Heijl A, Hyman L, Bengtsson B, Komaroff E. Factors for progression and glaucoma treatment: The early manifest glaucoma trial. Curr Opin Ophthalmol. 2004; 15: 102–106
   PubMedGoogle Scholar
• Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol Rev. 1992; 72: 449–489
   PubMed Web of Science ®Google Scholar
• Fisher J W. Erythropoietin: Physiology and pharmacology update. Exp Biol. Med. (Maywood). 2003; 228: 1–14
   PubMed Web of Science ®Google Scholar
• Mulcahy L. The erythropoietin receptor. Semin Oncol. 2001; 28: 19–23
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Misawa H. Physiology and function of the erythropoietin receptor. Curr Opin Hematol. 1998; 5: 171–176
   PubMedGoogle Scholar
• Anagnostou A, Lee E S, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA. 1990; 87: 5978–5982
   PubMed Web of Science ®Google Scholar
• Bernaudin M, Marti H H, Roussel S, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab. 1999; 19: 643–651
   PubMed Web of Science ®Google Scholar
• Campana W M, Misasi R, O'Brien J S. Identification of a neurotrophic sequence in erythropoietin. Int J Mol Med. 1998; 1: 235–241
   PubMed Web of Science ®Google Scholar
• Yu X, Shacka J J, Eells J B, et al. Erythropoietin receptor signaling is required for normal brain development. Development. 2002; 129: 505–516
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002; 8: 495–505
   PubMed Web of Science ®Google Scholar
• Celik M, Gokmen N, Erbayraktar S, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA. 2002; 99: 2258–2263
   PubMed Web of Science ®Google Scholar
• Gorio A, Gokmen N, Erbayraktar S, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA. 2002; 99: 9450–9455
   PubMed Web of Science ®Google Scholar
• Agnello D, Bigini P, Villa P, et al. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 2002; 952: 128–134
   PubMed Web of Science ®Google Scholar
• Leist M, Ghezzi P, Giovanni G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004; 305: 239–242
   PubMed Web of Science ®Google Scholar
• Gong H, Wang W, Kwon T H, et al. EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int. 2004; 66: 683–695
   PubMed Web of Science ®Google Scholar
• Nemoto T, Yokota N, Keane W F, Rabb H. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int. 2001; 59: 246–251
   PubMed Web of Science ®Google Scholar
• Patel N S, Sharples E J, Cuzzocrea S, et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 2004; 66: 983–989
   PubMed Web of Science ®Google Scholar
• Sharples E J, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004; 15: 2115–2124
   PubMed Web of Science ®Google Scholar
• Vesey D A, Cheung C, Pat B, Endre Z, Gobe G, Johnson D W. Erythropoietin protects against ischemic acute renal injury. Nephrol Dial Transplant. 2004; 19: 348–355
   PubMed Web of Science ®Google Scholar
• Yang C W, Li C, Jung J Y, et al. Preconditioning with erythropoietin protects against subsequent ischemia reperfusion injury in rat kidney. Faseb J. 2003; 17: 1754–1755
   PubMed Web of Science ®Google Scholar
• Grasso G, Meli F, Fodale V, Calapai G, Buemi M, Iacopino D G. Neuroprotective potential of erythropoietin and darbepoetin alfa in an experimental model of sciatic nerve injury. Laboratory investigation. J Neurosurg Spine. 2007; 7: 645–651
   PubMed Web of Science ®Google Scholar
• Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003; 100: 4802–4806
   PubMed Web of Science ®Google Scholar
• Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA. 2003; 100: 11612–11617
   PubMed Web of Science ®Google Scholar
• Parsa C J, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003; 112: 999–1007
   PubMed Web of Science ®Google Scholar
• Parsa C J, Kim J, Riel R U, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: A potential role for cardiac fibroblasts. J Biol Chem. 2004; 279: 20655–20662
   PubMed Web of Science ®Google Scholar
• Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med. 2002; 8: 718–724
   PubMed Web of Science ®Google Scholar
• Zhong L, Bradley J, Schubert W, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci. 2007; 48: 1212–1218
   PubMed Web of Science ®Google Scholar
• Rex T S, Allocca M, Domenici L, et al. Systemic but not intraocular EPO gene transfer protects the retina from light-and genetic-induced degeneration. Mol Ther. 2004; 10: 855–861
   PubMed Web of Science ®Google Scholar
• Grimm C, Wenzel A, Stanescu D, et al. Constitutive overexpression of human erythropoietin protects the mouse retina against induced but not inherited retinal degeneration. J Neurosci. 2004; 24: 5651–5658
   PubMed Web of Science ®Google Scholar
• Fu Q L, Wu W, Wang H, Li X, Lee V W, So K F. Up-regulated endogenous erythropoietin/erythropoietin receptor system and exogenous erythropoietin rescue retinal ganglion cells after chronic ocular hypertension. Cell Mol Neurobiol. 2008; 28: 317–329
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu Y, Jin Y, et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci. 2008; 49: 732–742
   PubMed Web of Science ®Google Scholar
• Zhu B, Wang W, Gu Q, Xu X. Erythropoietin protects retinal neurons and glial cells in early-stage streptozotocin-induced diabetic rats. Exp Eye Res. 2008; 86: 375–382
   PubMed Web of Science ®Google Scholar
• Junk A K, Mammis A, Savitz S I, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2002; 99: 10659–10664
   PubMed Web of Science ®Google Scholar
• Ranchon Cole I, Bonhomme B, Doly M. Pre-treatment of adult rats with high doses of erythropoietin induces caspase-9 but prevents light-induced retinal injury. Exp Eye Res. 2007; 85: 782–789
   PubMed Web of Science ®Google Scholar
• Weishaupt J H, Rohde G, Polking E, Siren A L, Ehrenreich H, Bahr M. Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci. 2004; 45: 1514–1522
   PubMed Web of Science ®Google Scholar
• Kilic U, Kilic E, Soliz J, Bassetti C I, Gassmann M, Hermann D M. Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/–2. Faseb J. 2005; 19: 249–251
   PubMedGoogle Scholar
• King C E, Rodger J, Bartlett C, Esmaili T, Dunlop S A, Beazley L D. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection. Exp Neurol. 2007; 205: 48–55
   PubMed Web of Science ®Google Scholar
• Tsai J C, Wu L, Worgul B, Forbes M, Cao J. Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma. Curr Eye Res. 2005; 30: 1025–1031
   PubMed Web of Science ®Google Scholar
• Hwang D, Tari S, Wu L, Chang S, Forbes M, Tsai J C. Retinal function assessment following intravitreal injection of erythropoietin in rats: A dose-toxicity study. Invest Ophthalmol Vis Sci. 2006; 47, E-Abstract 5724.
   Google Scholar
• Buckner F S, Eschbach J W, Haley N R, Davidson R C, Adamson J W. Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens. 1990; 3: 947–955
   PubMed Web of Science ®Google Scholar
• Dai C, Chung I J, Krantz S B. Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB. Exp Hematol. 2005; 33: 152–158
   PubMed Web of Science ®Google Scholar
• Wong C G, Rich K A, Liaw L H, Hsu H T, Berns M W. Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit. Curr Eye Res. 2001; 22: 140–147
   PubMed Web of Science ®Google Scholar
• Wachtmeister L. Oscillatory potentials in the retina: What do they reveal. Prog Retin Eye Res. 1998; 17: 485–521
   PubMed Web of Science ®Google Scholar
• Genc S, Koroglu T F, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci. 2004; 22: 105–119
   PubMed Web of Science ®Google Scholar
• Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005; 353: 782–792
   PubMed Web of Science ®Google Scholar
• Hardee M E, Cao Y, Fu P, et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE. 2007; 2: e549
   PubMed Web of Science ®Google Scholar
• Takagi H, Watanabe D, Suzuma K, et al. Novel role of erythropoietin in proliferative diabetic retinopathy. Diab Res Clin Pract. Sep, 2007; 77(S1)S62–64
   PubMedGoogle Scholar
• Ribatti D, Poliani P L, Longo V, Mangieri D, Nico B, Vacca A. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology. 2007; 50: 636–641
   PubMed Web of Science ®Google Scholar
• Sayan H, Ozacmak V H, Guven A, Aktas R G, Ozacmak I D. Erythropoietin stimulates wound healing and angiogenesis in mice. J Invest Surg. 2006; 19: 163–173
   PubMed Web of Science ®Google Scholar
• Hardee M E, Kirkpatrick J P, Shan S, et al. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer. 2005; 93: 1350–1355
   PubMed Web of Science ®Google Scholar
• Hale S A, Wong C, Lounsbury K M. Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells. Gynecol Oncol. 2006; 100: 14–19
   PubMed Web of Science ®Google Scholar
• Chen J, Connor K M, Aderman C M, Smith L E. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008; 118: 526–533
   PubMed Web of Science ®Google Scholar
• Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA. 2004; 101: 14907–14912
   PubMed Web of Science ®Google Scholar
• Grover S, Fishman G A, Birch D G, Locke K G, Rosner B. Variability of full-field electroretinogram responses in subjects without diffuse photoreceptor cell disease. Ophthalmology. 2003; 110: 1159–1163
   PubMed Web of Science ®Google Scholar
• Jacobi P C, Miliczek K D, Zrenner E. Experiences with the international standard for clinical electroretinography: Normative values for clinical practice, interindividual, and intraindividual variations and possible extensions. Doc Ophthalmol. 1993; 85: 95–114
   PubMed Web of Science ®Google Scholar
• Birch D G, Hood D C, Locke K G, Hoffman D R, Tzekov R T. Quantitative electroretinogram measures of phototransduction in cone and rod photoreceptors: Normal aging, progression with disease, and test-retest variability. Arch Ophthalmol. 2002; 120: 1045–1051
   PubMedGoogle Scholar
• Fishman G A, Chappelow A V, Anderson R J, Rotenstreich Y, Derlacki D J. Short-term inter-visit variability of erg amplitudes in normal subjects and patients with retinitis pigmentosa. Retina. 2005; 25: 1014–1021
   PubMed Web of Science ®Google Scholar
• Aydin E, Kazi A A, Peyman G A, Esfahani M R. Intravitreal toxicity of moxifloxacin. Retina. 2006; 26: 187–190
   PubMed Web of Science ®Google Scholar
• Manzano R P, Peyman G A, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006; 26: 257–261
   PubMed Web of Science ®Google Scholar
• Gitter S, Pardo A, Kariv N, Yinon U. Enhanced electroretinogram in cats induced by exposure to mercury acetate. Toxicology. 1988; 51: 67–76
   PubMed Web of Science ®Google Scholar